Fast Facts: Biosimilars in Hematology and Oncology: Biologics and biosimilars - getting decisions right
Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients.
Biologics and the need for biosimilars
Why do we need biosimilars?
How is the quality of biosimilar medicines assured?
Switching, interchangeability and extrapolation
Safety and pharmacovigilant
Formulary considerations: pharmacy issues
Formulary considerations: supportive care biosimilars
Formulary considerations: therapeutic anti-cancer biosimilars
Communication and awareness
Download citation file: